International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. · 2009

Read International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. by Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2694415.txt.

Introduction

Ambros and an international committee reported in 2009 a worldwide consensus on which gene tests should guide treatment of neuroblastoma, a childhood cancer of the nerve tissue. Doctors already used tumor genetics to match children to gentle or aggressive therapy. But countries ran different tests with different rules, so the same marker could mean different things in different hospitals.

The committee reviewed a shared database of 8,800 patients and compared each lab group's procedures in detail. Three markers earned a place in the new global risk system. They are the status of the MYCN gene, loss of a piece of chromosome 11, and the tumor's DNA content per cell. Standard procedures for measuring each were adopted, along with shared naming rules. Wider genome-wide panels are expected to join later. Uniform tests, the authors argue, make risk groups mean the same thing everywhere.

Catalog record

CREATORAmbros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2694415

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee By P F Ambros, I M Ambros, G M Brodeur, M Haber, J Khan, A Nakagawara, G Schleiermacher, F Speleman, R Spitz, W B London, S L Cohn, A D J Pearson Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6605014 ABSTRACT Abstract Neuroblastoma serves as a paradigm for utilising tumour genomic data for determining patient prognosis and treatment allocation. However, before the establishment of the International Neuroblastoma Risk Group (INRG) Task Force in 2004, international consensus on markers, methodology, and data interpretation did not exist, compromising the reliability of decisive genetic markers and inhibiting translational research efforts. The objectives of the INRG Biology Committee were to identify highly prognostic genetic aberrations to be included in the new INRG risk classification schema and to develop precise definitions, decisive biomarkers, and technique standardisation. The review of the INRG database (n=8800 patients) by the INRG Task Force finally enabled the identification of the most significant neuroblastoma biomarkers. In addition, the Biology Committee compared the standard operating procedures of different cooperative groups to arrive at international consensus for methodology, nomenclature, and future directions. Consensus was reached to include MYCN status, 11q23 allelic status, and ploidy in the INRG classification system on the basis of an evidence-based review of the INRG database. Standardised operating procedures for analysing these genetic factors were adopted, and criteria for proper nomenclature were developed. Neuroblastoma treatment planning is highly dependant on tumour cell genomic features, and it is likely that a comprehensive panel of DNA-based biomarkers will be used in future risk assignment algorithms applying genome-wide techniques. Consensus on methodology and interpretation is essential for uniform INRG classification and will greatly facilitate international and cooperative clinical and translational research studies. Keywords: neuroblastoma, treatment planning, genomic, translational, international consensus, INRG, genetic risk factors Modern treatment strategies adjust the therapy of cancer patients according to the predicted biological behaviour of the individual tumour. This is especially important for neuroblastoma patients, as a subset of neuroblastic tumours will undergo spontaneous regression (in infants and in young children) or maturation (in children), whereas others will rapidly progress despite intensive multimodality therapy. This clinical heterogeneity has been known for decades (D’Angio et al, 1971; Evans et al, 1976). However, patient age and tumour stage alone cannot reliably predict tumour behaviour. Over the past two decades, tumour histology, (Shimada et al, 1999) status of the MYCN oncogene, (Brodeur et al, 1984; Seeger et al, 1985), and tumour cell DNA content (ploidy; Look et al, 1991; Ladenstein et al, 2001) have each been shown to be independently predictive of patient outcome in large retrospective and prospective studies. Besides these two genetic markers, recently 11q aberrations were also included in the INRG pretreatment risk classification (Cohn et al, 2009). However, the optimal combination of these and additional recently described prognostic biomarkers to build a treatment stratification algorithm has not been determined yet. Here, we present the consensus of the INRG Biology Committee on which markers should be used currently, on the standardised operating procedures (SOPs; partly on the basis of SIOPEN activities (Ambros et al, 2003)) for analysing neuroblastoma tumour molecular diagnostics and genetic nomenclature in this rapidly evolving field. GENETIC FEATURES OF NEUROBLASTIC TUMOURS ASSOCIATED WITH FAVOURABLE CLINICAL BEHAVIOUR Favourable clinical behaviour of neuroblastic tumours is classically characterised by a propensity to undergo spontaneous regression or maturation without cytotoxic therapy (Figure 1). These tumours almost always show whole chromosome gains with few, if any, segmental chromosome aberrations and without gene amplifications. The DNA content is usually in the near-triploid (penta/hexaploid) range (Ambros et al, 1995, 1996; Brodeur, 2003; George et al, 2007; Mosse et al, 2007; Schleiermacher et al, 2007). This is also the case for the neuroblastic/ganglionic cell population in Schwann cell stroma-rich tumours, whereas the Schwann cell population itself has a diploid DNA content (Ambros et al, 1996; Bourdeaut et al, 2008). [Figure: Biological pathways and genetic features in neuroblastic tumours. Tumour cell ploidy (grey columns) can be used to subdivide neuroblastoma tumours into two broad groups (separated by the long punctuated line). Although the ploidy subgroups roughly correspond to the biologic subgroups (aggressive neuroblastomas marked by a red background – either with MYCN amplification in dark red and separated by a short punctuated line from neuroblastomas without MYCN amplification vs less aggressive behaving neuroblastomas indicated by a green background), they do not totally match. Although aggressive near-triploid neuroblastomas (in red below the long punctuated line) have been observed, it is less clear if ‘benign’ diploid neuroblastomas without any structural aberrations (in green above the long punctuated line) occur. ‘Benign’ clinical behaviour refers either to spontaneous regression/maturation without any therapy or with surgery only (no cytotoxic therapy).] Although tumour cell hyperdiploidy (usually near-triploid DNA content) is frequently associated with spontaneous maturation (Ambros et al, 1996) and possibly also with spontaneous regression, this ploidy level alone cannot guarantee benign tumour behaviour as near-triploid tumours may also have segmental chromosomal aberrations (i.e., gains or losses of only parts of chromosomes) and MYCN amplification, which can lead to clinically aggressive behaviour. GENETIC FEATURES OF NEUROBLASTIC TUMOURS ASSOCIATED WITH UNFAVOURABLE CLINICAL BEHAVIOUR Neuroblastomas with an unfavourable clinical behaviour (Figure 1) have a high propensity for locally invasive growth and widespread metastatic dissemination through the lymphatic and haematogenous systems. These tumours frequently show segmental aberrations and high-level amplification of the MYCN locus is detected in a substantial subset (Schwab et al, 1983; Brodeur et al, 1984; Seeger et al, 1985). MYCN amplification has been shown to be strongly associated with rapid tumour progression and poor prognosis in patients of all ages, with any stage of disease (Brodeur et al, 1984; Seeger et al, 1985; Ambros et al, 1995; Perez et al, 2000). As expected, MYCN amplification was also highly predictive of worse outcome in the INRG cohort of patients (Cohn et al, 2009). Frequently, adjacent or more distantly located genes, such as DDX1, NAG, and ALK, are coamplified with MYCN, but amplification events in the absence of MYCN amplification are rare. Whether these coamplifications have a prognostic impact awaits clarification (Manohar et al, 1995; Squire et al, 1995; George et al, 1997; De Preter et al, 2002; Weber et al, 2004). Although MYCN status is central to the risk stratification systems in all cooperative clinical trial groups, it is important to emphasise that the majority of metastatic neuroblastomas do not show amplification of this oncogene (see also Figure 1). Other chromosomal aberrations (and a diploid DNA content) have been assumed to predict unfavourable tumour behaviour, including deletion at the chromosomal region 1p36.3 or 11q23, (Maris et al, 1995; Caron et al, 1996b; Attiyeh et al, 2005) as well as unbalanced gain of the long arm of chromosome 17 (17q21 to 17qter; Caron, 1995; Bown et al, 1999; Spitz et al, 2003). In addition, some studies have shown that deletions on chromosome 3p, 4p, 9p, and 12p also have prognostic significance (Caron et al, 1996a; Thompson et al, 2001; Schleiermacher et al, 2007). As 11q deletions are inversely associated with MYCN amplification, this aberration has emerged as a powerful biomarker of outcome in cases without MYCN amplification (Attiyeh et al, 2005). Statistical analysis of the

Read the complete text